Last updated: 21.02.2019


Zensun focuses on leading-edge research and development of mechanism-based healthcare solutions. The current pipeline includes cardiovascular disease treatment and treatments for energy metabolism disorders. The first-in-class drug Neucardin™, which addresses wholly innovative targets and mechanisms, is now in phase III clinical trials and will bring revolutionary innovations in cardiomyocyte therapy. After more than ten years of research and development, Zensun’s product line of innovative drugs and medical instruments with short, medium, or long-term horizons for commercialization is ready to begin appearing in the global market, and Zensun will become an integrated company doing research, production, and sales.


Juli Road No. 68, Zhangjiang Hi-tech Park, Pudong, Shanghai, China

Tel: +86 21 50802627

Website: http://www.zensun.com/



We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here